SNAP-37889

Galanin is co-localized with serotonin in the dorsal raphe nucleus and with norepinephrine in the locus coeruleus, and centrally administered galanin inhibits serotonergic transmission, producing a long-lasting reduction in hippocampal serotonin release. This anatomy made the galanin system a compelling but under-drugged target for mood disorders. The obstacle was the absence of subtype-selective ligands. SNAP-37889 and its soluble analog SNAP-398299 were introduced as potent, brain-penetrant, GAL3-selective antagonists to test the hypothesis that blocking GAL3 would be antidepressant and anxiolytic ^[1].

Behaviorally, both compounds delivered. Acute SNAP-37889 or SNAP-398299 enhanced rat social interaction, and SNAP-37889 reduced separation-induced guinea-pig vocalizations, attenuated stress-induced hyperthermia, increased punished drinking, and decreased immobility while increasing swimming in the forced-swim test. The effects were durable, with maintained social-interaction benefit after fourteen days and antidepressant effects after twenty-one days of treatment ^[1]. Neurochemically and electrophysiologically, SNAP-37889 partially reversed galanin's inhibition of hippocampal serotonin, and SNAP-398299 partially reversed galanin-evoked inhibition of dorsal raphe cell firing and hyperpolarizing currents, tying the behavioral effects to disinhibited serotonergic tone ^[1].

A broader review of galanin receptor antagonists concluded that antidepressant efficacy is likely associated with antagonism at GAL3 and possibly GAL1, or agonism at GAL2, framing SNAP-37889 as the flagship GAL3-antagonist tool for this thesis ^[2]. Practical use has been constrained by very poor aqueous solubility, prompting the development of specialized injectable microemulsion formulations to enable in vivo rodent studies ^[3]. GAL3 antagonism has also been explored in alcohol and drug-seeking behavior. Together these compounds established GAL3 as a mechanistically plausible antidepressant and anxiolytic target, even though neither advanced to human therapeutic use.

These are preclinical compounds with no human safety data. The most practical limitation is very poor aqueous solubility, which required specialized microemulsion vehicles for reliable dosing in animals. Because GAL3 antagonism modulates monoaminergic tone, theoretical risks include serotonergic and autonomic effects, though these were not characterized as adverse in the rodent studies. No formal toxicology, reproductive, or long-term safety data have been published.

SNAP-37889 and SNAP-398299 originated from the Synaptic Pharmaceutical and Lundbeck research lineage, with Branchek, Walker, and colleagues characterizing their GAL3-selective antagonism and mood effects in a 2005 report. The work was contextualized by Karolinska-based reviews from Ogren and Hokfelt on galanin's role in depression. The compounds became reference tools for GAL3 pharmacology, and later Australian groups developed improved injectable formulations to extend their use into addiction research.

In neuropeptide psychopharmacology SNAP-37889 is the canonical GAL3-selective antagonist and is repeatedly cited as evidence that GAL3 blockade is anxiolytic and antidepressant. It validated GAL3 as a target concept but did not itself become a drug, partly due to solubility and partly because the galanin field is niche. It is unknown in consumer and nootropic contexts and available only as a research reagent.